KURA Kura Oncology Inc.

15.61
+0.4  (+3%)
Previous Close 15.21
Open 15.25
Price To Book 3.03
Market Cap 707,362,217
Shares 45,314,684
Volume 399,861
Short Ratio
Av. Daily Volume 239,151
Stock charts supplied by TradingView

NewsSee all news

  1. Kura Oncology to Participate in Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today

  2. Kura Oncology to Present at Stifel Healthcare Conference

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today

  3. Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting

    SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced

  4. Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation

  5. Kura Oncology Appoints James Basta as Chief Legal Officer

    SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 1H 2020.
Tipifarnib
Chronic myelomonocytic leukemia (CMML) - cancer
Phase 2 data due at ASH December 8, 2019 at 1:15pm ET.
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2 full enrolment due by end of 2020.
Tipifarnib - (AIM-HN/SEQ-HN)
Head and neck squamous cell carcinomas (HNSCC)
Phase 1 trial completion late-2019 / early 2020.
KO-947
Solid tumors
Phase 2 data presented at AACR-NCI-EORTC October 29, 2019 noted PFS 6.1 months. 10/18 partial responses.
Tipifarnib
Head and neck squamous cell carcinomas (HNSCC) with HRAS Mutations
Phase 1 initiation of dosing announced September 16, 2019. Recommended Phase 2 dose due 2020.
KO-539
Relapsed or refractory acute myeloid leukemia (AML)
Phase 2 data due 2020.
Tipifarnib
HRAS Mutant Urothelial Carcinoma

Latest News

  1. Kura Oncology to Participate in Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today

  2. Kura Oncology to Present at Stifel Healthcare Conference

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today

  3. Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting

    SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced

  4. Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation

  5. Kura Oncology Appoints James Basta as Chief Legal Officer

    SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced

  6. Kura Oncology to Report Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced

  7. Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

    – 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% – – Median progression-free survival of 6.1 months vs. 2.8 months on last prior therapy – – 8

  8. Kura Oncology Expands Board of Directors with Appointment of Diane Parks

    SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced

  9. Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia

    – KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) --

  10. Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma

    – Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater than 6 months – –

  11. Kura Oncology to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced